Steroidal Compounds Inhibiting Steroid Sulphatase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for breast cancer, particularly hormone-dependent breast cancer, are limited by the inefficacy of aromatase inhibitors in reducing estrogen levels, as other pathways like the sulphatase pathway contribute significantly to estrogen synthesis, necessitating the development of new therapies to inhibit the oestrone sulphatase and steroid dehydrogenase pathways.
Innovation Solution
Development of novel compounds that inhibit steroid sulphatase (STS) and steroid dehydrogenase (HSD) enzymes, which are key in the biosynthesis of estrogens, to block the conversion of oestrone to oestradiol, thereby reducing estrogen levels in the body and inhibiting breast cancer growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aromatase inhibitors are used to reduce estrogen levels, then breast cancer treatment is provided, but the treatment becomes ineffective because other pathways like the sulphatase pathway contribute significantly to estrogen synthesis
Solution Approach 1:
The patent develops compounds that can inhibit multiple enzymes involved in estrogen synthesis, including both aromatase and steroid sulphatase. This multi-functional approach ensures comprehensive blockade of estrogen production pathways, preventing the tumor from utilizing alternative routes to maintain estrogen levels.
Solution Approach 2:
The invention divides the estrogen synthesis pathway into distinct targets (aromatase enzyme and steroid sulphatase enzyme) and develops inhibitors for each segment. By addressing each pathway separately with specific inhibitors, the treatment comprehensively blocks all major routes of estrogen production.
2Reliability
If novel compounds inhibiting both STS and HSD are developed, then therapeutic advantage is achieved, but treatment complexity increases
Solution Approach 1:
The patent merges the inhibition of two different enzymes (steroid sulphatase and steroid dehydrogenase) into a single therapeutic compound or combination regimen. This consolidation approach achieves multi-enzyme inhibition while simplifying the treatment protocol, as the compounds can be administered together as a unified therapy rather than separate complex interventions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit STS and HSD activities, providing a therapeutic advantage in treating breast and endometrial cancers by reducing estrogen levels and potentially offering a more potent approach than existing aromatase inhibitors.
Implementation Method 1
These compounds effectively inhibit STS and HSD activities, providing a therapeutic advantage in treating breast and endometrial cancers by reducing estrogen levels
Data Source
Figure 1
Figure 2
Figure 3
AI summary
There is provided a compound having Formula (I): wherein G is a fluorocarbyl group, and wherein R1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group, capable of inhibiting steroid sulphatase.